comparemela.com

Page 8 - Abcam Daily News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Financial Comparison: Abcam (ABCZF) vs Its Competitors

Abcam (OTCMKTS:ABCZF – Get Free Report) is one of 449 public companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Abcam to similar businesses based on the strength of its profitability, risk, valuation, analyst recommendations, institutional ownership, dividends and earnings. Profitability This table compares Abcam and […]

Critical Review: Abcam (ABCZF) & Its Peers

Abcam (OTCMKTS:ABCZF – Get Free Report) is one of 397 public companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Abcam to similar businesses based on the strength of its dividends, risk, valuation, profitability, earnings, institutional ownership and analyst recommendations. Dividends Abcam pays an annual dividend […]

Short Interest in Abcam plc (NASDAQ:ABCM) Expands By 92 3%

Abcam plc (NASDAQ:ABCM – Get Free Report) saw a significant growth in short interest in June. As of June 30th, there was short interest totalling 1,480,000 shares, a growth of 92.3% from the June 15th total of 769,800 shares. Based on an average daily trading volume, of 1,550,000 shares, the short-interest ratio is currently 1.0 […]

Abcam (ABCZF) and The Competition Head to Head Analysis

Abcam (OTCMKTS:ABCZF – Get Free Report) is one of 380 public companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare Abcam to similar companies based on the strength of its dividends, profitability, earnings, institutional ownership, risk, valuation and analyst recommendations. Insider and Institutional Ownership 43.6% of […]

Contrasting Abcam (ABCZF) & Its Rivals

Abcam (OTCMKTS:ABCZF – Get Free Report) is one of 386 public companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Abcam to related businesses based on the strength of its analyst recommendations, earnings, valuation, risk, dividends, profitability and institutional ownership. Analyst Ratings This is a summary of recent […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.